Lenvatinib (Kisplyx®). HTA ID: 22057

Assessment Status Rapid Review Complete
HTA ID 22057
Drug Lenvatinib
Brand Kisplyx®
Indication For the treatment of adults with advanced renal cell carcinoma, in combination with pembrolizumab, as first-line treatment
Assessment Process
Rapid review commissioned 15/08/2022
Rapid review completed 22/09/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of lenvatinib in combination with pembrolizumab for first-line treatment of patients with advanced RCC compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.